CUSIP: 24343R106
Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
17,868,680
-
Share change
-
+177,387
-
Total reported value
-
$75,221,250
-
Put/Call ratio
-
25%
-
Price per share
-
$4.21
-
Number of holders
-
41
-
Value change
-
+$1,834,530
-
Number of buys
-
18
-
Number of sells
-
18
Quarterly Holders Quick Answers
What is CUSIP 24343R106?
CUSIP 24343R106 identifies DBTX - DECIBEL THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2022
-
Previous quarter:
Q1 2022
Recent filing periods for CUSIP 24343R106:
Institutional Holders of DECIBEL THERAPEUTICS INC - COM (DBTX) as of Q2 2022
As of 30 Jun 2022,
DECIBEL THERAPEUTICS INC - COM (DBTX) was held by
41 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
17,868,680 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, TRV GP III, LLC, BlackRock Inc., CITADEL ADVISORS LLC, Alphabet Inc., Samsara BioCapital, LLC, VANGUARD GROUP INC, BESSEMER GROUP INC, HARVARD MANAGEMENT CO INC, and Newtyn Management, LLC.
This page lists
41
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.